MSB News and Press, Mesabi Trust From 04/29/25

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. “We were very pleased to have ...

2025-04-29 08:59:05 ET Mesabi Trust (MSB) declaring a stock dividend of $0.56 per share on Ex-Date : April 30, 2025. Shareholders on record as of April 30, 2025 are eligible for the dividend. The payment date is scheduled for May 20, 2025, and the declaration was officially made on ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services indust...

Plexus Corp. (PLXS) is expected to report $1.32 for Q2 2025 VinFast Auto Ltd. (VFS) is expected to report $-0.21 for Q1 2024 Alaska Air Group Inc. (ALK) is expected to report $-0.72 for Q1 2025 Travelzoo (TZOO) is expected to report $0.25 for Q1 2025 M/I Homes Inc. (MHO) is expect...

2025-04-22 18:48:51 ET Mesabi Trust (MSB) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.41%. The average open to low on the day of earnings was -1.65%. The average open to close on t...

2025-04-22 18:43:50 ET Mesabi Trust (MSB) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in MSB stock price following earnings has averaged ±1.42% , with a median of 0.72%. The singl...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil ® (remestemcel-L), the first mesenchymal stromal cell (MSC) therap...

2025-04-16 09:39:38 ET More on Mesabi Trust Mesabi Trust: Volume Recovery Means Royalty Rates Ratchet Up Dividend scorecard for Mesabi Trust Financial information for Mesabi Trust Read the full article on Seeking Alpha For further details see: Mes...

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval path...